Allergan announced that the Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Applications (sBLAs) for Botox (onabotulinumtoxinA) injection for the treatment of patients aged ≥2 years with upper and lower limb spasticity.

The sBLA submissions were supported by data from four phase 3 studies evaluating the safety and efficacy of Botox in >600 pediatric patients (235 patients with upper limb spasticity due to cerebral palsy or stroke and 384 patients with lower limb spasticity due to cerebral palsy). In the 2 placebo-controlled trials (NCT01603628; NCT01603602), Botox significantly decreased spasticity vs placebo, as measured by the average change from baseline in Modified Ashworth Scale-Bohannon (MAS-B) score.

Botox, an acetylcholine release inhibitor and a neuromuscular blocking agent, is currently approved to treat increased muscle stiffness in elbow, wrist, finger, thumb, ankle, and toe muscles in patients aged ≥18 years with upper and lower limb spasticity. If approved, it would be the first neurotoxin indicated to treat both upper and lower limb pediatric spasticity.

Related Articles

The FDA has set a Prescription Drug User Fee Act (PDUFA) date for the upper limb pediatric spasticity indication in the second quarter of 2019; the PDUFA date for the lower limb pediatric spasticity indication is expected in the fourth quarter of 2019.

For more information visit Allergan.com.